Literature DB >> 22294404

Methods of inducing inflammatory bowel disease in mice.

Joseph R Maxwell1, William A Brown, Carole L Smith, Fergus R Byrne, Joanne L Viney.   

Abstract

Animal models of experimentally induced inflammatory bowel disease (IBD) are useful for understanding more about the mechanistic basis of disease, identifying new targets for therapeutic intervention, and testing novel therapeutic agents. This unit provides detailed protocols for four of the most commonly used mouse models of experimentally induced intestinal inflammation: chemical induction of colitis by dextran sodium sulfate (DSS), hapten-induced colitis via 2,4,6-trinitrobenzene sulfonic acid (TNBS), Helicobacter-induced colitis in mdr1a(-/-) mice, and the CD4(+) CD45RB(hi) SCID transfer colitis model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 22294404     DOI: 10.1002/0471141755.ph0558s47

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  20 in total

1.  Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota.

Authors:  You Jin Jang; Woon-Ki Kim; Dae Hee Han; Kiuk Lee; Gwangpyo Ko
Journal:  Gut Microbes       Date:  2019-04-03

Review 2.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

3.  Mesenchymal stromal cells modulate gut inflammation in experimental colitis.

Authors:  Cristhiane Favero de Aguiar; Angela Castoldi; Vinícius Andrade-Oliveira; Aline Ignacio; Flávia Franco da Cunha; Raphael José Ferreira Felizardo; Ênio José Bassi; Niels Olsen Saraiva Câmara; Danilo Candido de Almeida
Journal:  Inflammopharmacology       Date:  2017-10-23       Impact factor: 4.473

4.  RNA Purity, Real-Time PCR Sensitivity, and Colon Segment Influence mRNA Relative Expression in Murine Dextran Sodium Sulfate Experimental Colitis.

Authors:  Bernardo Oldak; Mayra Cruz-Rivera; Ana Flisser; Fela Mendlovic
Journal:  J Biomol Tech       Date:  2018-07-13

5.  Branched Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) Protect against Colitis by Regulating Gut Innate and Adaptive Immune Responses.

Authors:  Jennifer Lee; Pedro M Moraes-Vieira; Angela Castoldi; Pratik Aryal; Eric U Yee; Christopher Vickers; Oren Parnas; Cynthia J Donaldson; Alan Saghatelian; Barbara B Kahn
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

6.  IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.

Authors:  J C Martin; G Bériou; M Heslan; C Bossard; A Jarry; A Abidi; P Hulin; S Ménoret; R Thinard; I Anegon; C Jacqueline; B Lardeux; F Halary; J-C Renauld; A Bourreille; R Josien
Journal:  Mucosal Immunol       Date:  2015-09-02       Impact factor: 7.313

7.  Regulatory T-cell depletion in the gut caused by integrin β7 deficiency exacerbates DSS colitis by evoking aberrant innate immunity.

Authors:  H L Zhang; Y J Zheng; Y D Pan; C Xie; H Sun; Y H Zhang; M Y Yuan; B L Song; J F Chen
Journal:  Mucosal Immunol       Date:  2015-07-29       Impact factor: 7.313

8.  PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

Authors:  Yunpeng Qi; Changtao Jiang; Naoki Tanaka; Kristopher W Krausz; Chad N Brocker; Zhong-Ze Fang; Bryce X Bredell; Yatrik M Shah; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-17       Impact factor: 4.052

9.  Ron receptor signaling is protective against DSS-induced colitis in mice.

Authors:  Rishikesh M Kulkarni; William D Stuart; Devikala Gurusamy; Susan E Waltz
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

10.  Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Authors:  F L Scott; B Clemons; J Brooks; E Brahmachary; R Powell; H Dedman; H G Desale; G A Timony; E Martinborough; H Rosen; E Roberts; M F Boehm; R J Peach
Journal:  Br J Pharmacol       Date:  2016-04-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.